# European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal Therapies

> **NCT05043506** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 1939 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Palbociclib + aromatase inhibitor
- **DRUG:** Aromatase inhibitor

## Key facts

- **NCT ID:** NCT05043506
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-08
- **Primary completion:** 2023-11-02
- **Final completion:** 2023-11-02
- **Target enrollment:** 1939 (ACTUAL)
- **Last updated:** 2024-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05043506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05043506, "European Treatment Patterns and Outcomes Associated With First-Line CDK4/6 Inhibition and Hormonal Therapies". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT05043506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*